

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
16 November 2023 (16.11.2023)



(10) International Publication Number
WO 2023/220349 A1

(51) International Patent Classification:
C12N 15/113 (2010.01)

(21) International Application Number:
PCT/US2023/022005

(22) International Filing Date:
12 May 2023 (12.05.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/364,609 12 May 2022 (12.05.2022) US

(71) Applicant: **DICERNA PHARMACEUTICALS, INC.**
[US/US]; 75 Hayden Avenue, Lexington, Massachusetts
02421 (US).

(72) Inventors: **BROWN, Bob, Dale**; c/o Dicerna Pharmaceu-
ticals, Inc., 75 Hayden Avenue, Lexington, Massachusetts
02421 (US). **DUDEK, Henryk, T.**; c/o Dicerna Pharmaceu-
ticals, Inc., 75 Hayden Avenue, Lexington, Massachusetts
02421 (US). **CHEONG, Seongmoon**; c/o Dicerna Pharma-
ceuticals, Inc., 75 Hayden Avenue, Lexington, Massachu-
setts 02421 (US). **WANG, Shiyu**; c/o Dicerna Pharmaceu-
ticals, Inc., 75 Hayden Avenue, Lexington, Massachusetts
02421 (US). **GRIM, Travis**; c/o Dicerna Pharmaceuticals,
Inc., 75 Hayden Avenue, Lexington, Massachusetts 02421
(US). **COSTALES, Matthew, Guese**; c/o Dicerna Pharma-
ceuticals, Inc., 75 Hayden Avenue, Lexington, Massachu-
setts 02421 (US). **JUNG, Maire**; c/o Dicerna Pharmaceu-
ticals, Inc., 75 Hayden Avenue, Lexington, Massachusetts
02421 (US).

(74) Agent: **REID, Andrea, L.C.** et al.; c/o Dechert LLP, One
International Place, 40th Floor, 100 Oliver Street, Boston,
Massachusetts 02110-2605 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: COMPOSITIONS AND METHODS FOR INHIBITING *MAPT* EXPRESSION

(57) Abstract: Oligonucleotides are provided herein that inhibit *MAPT* gene expression, including oligonucleotides conjugated to a targeting ligand (e.g., lipid moiety). Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders, and/or conditions associated with *MAPT* gene expression.

WO 2023/220349 A1